Sustained Alzheimer's amyloid pathology in myeloid differentiation protein-88-deficient APPswe/PS1 mice

Neurodegener Dis. 2014;13(2-3):58-60. doi: 10.1159/000353689. Epub 2013 Oct 30.

Abstract

Background: Most Alzheimer's disease (AD) cases arise sporadically and may involve innate immune activation of microglial expressed Toll-like receptors regulated through the myeloid differentiation protein 88 (MyD88) pathway.

Objective: It was the aim of this study to test the innate immune involvement in AD pathology.

Methods: We mated APPsw/PS1ΔE9 mice with MyD88-deficient mice.

Results: Progeny mice had similar levels of soluble amyloid-β peptides, amyloid plaque density and neuroimmune staining patterns. However, double-transgenic mice did show a significantly reduced life expectancy.

Conclusion: Our findings indicate that impaired innate immune responses may play a role in AD pathology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / immunology*
  • Alzheimer Disease / metabolism*
  • Alzheimer Disease / pathology*
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Brain / immunology
  • Brain / metabolism
  • Brain / pathology*
  • Disease Models, Animal
  • Enzyme-Linked Immunosorbent Assay
  • Fluorescent Antibody Technique
  • Mice
  • Mice, Transgenic
  • Myeloid Differentiation Factor 88 / deficiency*
  • Plaque, Amyloid / pathology
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Amyloid beta-Peptides
  • Myd88 protein, mouse
  • Myeloid Differentiation Factor 88